Corvus Pharma Reports Executive/Director Changes, Comp Arrangements

TL;DR

**Corvus Pharma just filed an 8-K about executive changes and pay, keep an eye on leadership.**

AI Summary

Corvus Pharmaceuticals, Inc. filed an 8-K on January 23, 2024, to report a 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' and 'Other Events.' This filing indicates changes in leadership or executive compensation, which could signal strategic shifts or financial adjustments within the company. For investors, these changes are important because they can impact future company performance, governance, and ultimately, stock value.

Why It Matters

Changes in executive leadership or compensation can signal strategic shifts, potential operational improvements, or financial restructuring, directly influencing investor confidence and the company's future direction.

Risk Assessment

Risk Level: medium — Changes in leadership or compensation can introduce uncertainty, but the specific details are not yet public, making the exact impact unclear.

Analyst Insight

A smart investor would monitor Corvus Pharmaceuticals' subsequent filings and press releases for specific details on the executive changes and compensation arrangements, as these will clarify the strategic implications and potential impact on the company's future performance.

Key Numbers

• January 23, 2024 — Date of Report (The date the earliest event reported in the 8-K occurred.)
• $0.0001 — Par Value per share (The par value of Corvus Pharmaceuticals' Common Stock.)

Key Players & Entities

• Corvus Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
• Nasdaq Global Market (company) — the exchange where Corvus Pharmaceuticals' Common Stock is registered
• 001-37719 (dollar_amount) — Commission File Number
• 46-4670809 (dollar_amount) — I.R.S. Employer Identification No.
• 863 Mitten Road, Suite 102 Burlingame, California 94010 (person) — Address of Principal Executive Offices
• (650) 900-4520 (person) — Registrant's telephone number

Forward-Looking Statements

• Further details regarding the specific executive changes and compensation arrangements will be disclosed in subsequent filings or press releases. (Corvus Pharmaceuticals, Inc.) — high confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, Par Value $0.0001 per share CRVS Nasdaq Global Market I

Filing Documents

• f8k_012324.htm (8-K) — 14KB
• exh_991.htm (EX-99.1) — 3KB
• 0001171843-24-000360.txt ( ) — 212KB
• gnw-20190101.xsd (EX-101.SCH) — 3KB
• gnw-20190101_def.xml (EX-101.DEF) — 25KB
• gnw-20190101_lab.xml (EX-101.LAB) — 33KB
• gnw-20190101_pre.xml (EX-101.PRE) — 22KB
• f8k_012324_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events. On January 23, 2024, Corvus Pharmaceuticals, Inc. issued a press release regarding the death of Dr. Mitchell, a copy of which is included as Exhibit 99.1 to this Form 8-K.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 99.1 Press release of Corvus Pharmaceuticals, Inc. dated January 23, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Corvus Pharmaceuticals, Inc. Date: January 23, 2024 By: /s/ Leiv Lea Leiv Lea Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR